SAGENT PHARMS INC
GenericsSAGENT PHARMS INC is a generic drug manufacturer focused on Infectious Disease, Dermatology, Oncology.
SAGENT PHARMS INC's Key Drugs
SAGENT PHARMS INC's core commercial portfolio centers on GLYDO, spanning Infectious Disease and Dermatology — its most strategically important drugs approved in the last 15 years.
SAGENT PHARMS INC's Recent FDA Approvals
SAGENT PHARMS INC secured 3 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
SAGENT PHARMS INC's Therapeutic Areas
SAGENT PHARMS INC's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Dermatology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SAGENT PHARMS INC's Top Competitors
SAGENT PHARMS INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Bristol-Myers Squibb, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SAGENT PHARMS INC Pipeline Snapshot
Active clinical trials for SAGENT PHARMS INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • GLYDO leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1999-01-04
- Latest
- 2026-03-13
- Applications
- 79